Pages
-
-
Guidelines of the International Headache Society for controlled clinical trials in idiopathic intracranial hypertension
-
-
Headache attributed to SARS-CoV-2 infection, vaccination and the impact on primary headache disorders of the COVID-19 pandemic
-
-
Guidelines of the International Headache Society for controlled clinical trials in cluster headache
-
-
Guidelines of the International Headache Society for Clinic-Based Headache Registries, 1(st) edition
-
-
Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice
-
-
Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice:
-
-
Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study
-
-
Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world
-
-
Diagnosis and management of migraine in ten steps
-
-
Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine
-
-
Atrial fibrillation and comorbidities
-
-
Health technology assessment for the acute and preventive treatment of migraine
-
-
Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation
-
-
Characteristics and 2-year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation
-
-
Guidelines for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults
-
-
Persistence with anticoagulation for atrial fibrillation
-
-
Stroke prevention in atrial fibrillation changes after dabigatran availability in China
-
-
Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program
-
-
Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial
-
-
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
-
-
Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults
-
-
Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition
-
-
Rationale, design, and protocol of a randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous thrombosis
-
-
Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program
Pages